Glanzmann’s disease is a rare disorder of blood platelets
, which results in easy bruising
Causes, incidence, and risk factors
Glanzmann's disease is caused by the lack of a protein that is normally on the surface of platelets, which is needed for them to clump together (aggregate) normally.
The condition is congenital, which means it is present from birth. There are several genetic abnormalities that can cause the condition.
- Bleeding during and after surgery
- Bleeding gums
- Easy bruising
- Heavy menstrual bleeding
- Nosebleeds (epistaxis)
- Prolonged bleeding with minor injuries
Signs and tests
The following tests may be used to diagnose this condition:
Other tests may be needed, including the testing of relatives.
There is no specific treatment for this disorder. Platelet transfusions may be given to patients who are having severe bleeding.
Glanzmann's thrombasthenia is a life-long condition for which there is no cure. Patients should take precautions to avoid bleeding.
Anyone with a bleeding disorder should avoid taking aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and naproxen. These drugs can prolong bleeding times and prevent platelets from activating and aggregating.
Calling your health care provider
Call your health care provider if:
A blood test can detect the gene responsible for the condition.
Genetic counseling may be helpful to couples with a family history of platelet disorders who are planning to have children in the future.
Bennett JS. Hereditary disorders of platelet function. In: Hoffman R, Benz EJ Jr., Shattil SJ, et al, eds. Hoffman Hematology: Basic Principles and Practice. 5th ed. Philadelphia, Pa: Churchill Livingstone Elsevier; 2008:chap 141.
McMillan R. Hemorrhagic disorders: Abnormalities of platelet and vascular function. In: Goldman L, Ausiello D, eds. Cecil Medicine. 23rd ed. Philadelphia, Pa: Saunders Elsevier; 2007:chap 179.
David C. Dugdale, III, MD, Professor of Medicine, Division of General Medicine, Department of Medicine, University of Washington School of Medicine; and Yi-Bin Chen, MD, Leukemia/Bone Marrow Transplant Program, Massachusetts General Hospital. Also reviewed by David Zieve, MD, MHA, Medical Director, A.D.A.M., Inc.